GENEVA _ Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44 percent of biotech pioneer Genentech that it doesn't already own, ending a long corporate struggle with its U.S.-based cancer drug partner.
GENEVA _ Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44 percent of biotech pioneer Genentech that it doesn't already own, ending a long corporate struggle with its U.S.-based cancer drug partner.